Here’s Why GreensKeeper Asset Management Added Novo Nordisk (NVO) to Its Portfolio

GreensKeeper Asset Management, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Value Fund has reached the midpoint of 2025, recording a decline of -3.6% net of fees and expenses. The US dollar has experienced a substantial depreciation, negatively impacting performance by over 5.0% year-to-date (YTD). The fund’s robust beginning in Q1 was reversed in Q2 as markets shrugged off President Trump’s “Liberation Day” tariffs and adopted a full “risk on” stance. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025.

In its second-quarter 2025 investor letter, GreensKeeper Asset Management highlighted stocks such as Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages in the research and development, manufacture, and distribution of pharmaceutical products. The one-month return of Novo Nordisk A/S (NYSE:NVO) was -17.42%, and its shares lost 57.89% of their value over the last 52 weeks. On August 22, 2025, Novo Nordisk A/S (NYSE:NVO) stock closed at $56.98 per share, with a market capitalization of $246.974 billion.

Burke Wealth Management stated the following regarding Novo Nordisk A/S (NYSE:NVO) in its second quarter 2025 investor letter:

“We made one new purchase in the quarter: Novo Nordisk A/S (NYSE:NVO), which we have owned previously. NVO, a Danish pharmaceutical company, is the world’s leading insulin maker. But today the company’s growth is driven by its GLP-1 franchise, which comprises Ozempic, Wegovy and Rybelsus. The stock has come under pressure following the uptake of competitor Eli Lilly’s (LLY) GLP-1 products Mounjaro and Zepbound. LLY will likely continue to gain share, but we believe the market for GLP-1s is large enough for both companies to continue increasing their revenues, and that the market is undervaluing NVO’s GLP-1 pipeline.”

In another article, we covered Novo Nordisk A/S (NYSE:NVO) and shared the list of Jim Cramer talked about. Burke Wealth Management sold its stake in Novo Nordisk A/S (NYSE:NVO) in Q2 2025, after its new obesity treatment, Cagri-Sema, underperformed compared to Eli Lilly’s Zepbound. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.